Is there a role for surgery for microprolactinomas?

Seminars in Neurosurgery

Volumn 12, Issue 3, 2001, Pages 289-294

  Wang, Michael Y ^a   Weiss, Martin H ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Bromocriptine; Pituitary adenoma; Prolactinoma; Transsphenoidal surgery

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LISURIDE; PERGOLIDE; PROLACTIN; PROTIRELIN; QUINAGOLIDE;

AGE; ARTICLE; CANCER RADIOTHERAPY; CLINICAL TRIAL; HORMONAL THERAPY; HUMAN; HYPERPROLACTINEMIA; HYPOTHYROIDISM; MACROADENOMA; MICROADENOMA; NEUROSURGERY; PREGNANCY; PROLACTINOMA; STEREOTAXIC SURGERY; TRANSSPHENOIDAL SURGERY;

EID: 0035468325     PISSN: 15268012     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-33619     Document Type: Article

References (36)

1. Pituitary tumors
2. Subclinical adenoma of the pituitary gland
3. Pathology of pituitary tumors
4. Incidental pituitary adenomas
5. Mechanisms for hypogonadism in hyperprolactinemia
6. Pituitary tumor: An endocrinological and neurosurgical challenge
7. Long-term follow-up of 246 hyperprolactinemic patients
8. Natural history of microprolactinomas: Six-year follow-up
9. Medical and surgical management of functional pituitary tumors
10. Successful treatment of a prolactin-producing pituitary macroadenoma with intravaginal bromocriptine mesylate: A novel approach to intolerance of oral therapy
11. Pituitary disorders: Drug treatment options
12. Primary medical therapy of micro- and macro-prolactinomas in men
13. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea
14. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas
15. Management of prolactinomas during pregnancy
16. Clinical course and outcome of pregnancy in twenty-five patients with pituitary microadenomas
17. Effects of estrogen on primary ovine pituitary cell cultures: Stimulation of prolactin secretion, synthesis and prolactin messenger ribonucleic acid levels
18. Medical treatment of prolactinomas
19. Hypopituitarism following external radiotherapy for pituitary tumors in adults
20. Gamma knife radiosurgery as a primary treatment for prolactinomas
21. Gamma knife radiosurgery for prolactinomas
22. Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas
23. Prolactinomas express human heparin-binding secretory transforming gene (hst) protein product: Marker of tumour invasiveness
24. Transforming gene from human stomach cancers and a noncancerous portion of stomach mucosa
25. Expression of the K-fgf proto-oncogene is repressed during differentiation of F9 cells
26. Chromosomal localization of the hst oncogene and its co-amplification with the int.2 oncogene in human melanoma
27. Management of prolactin-secreting pituitary adenomas
28. Treatment options in the management of prolactin-secreting pituitary tumors
29. Prolactin secreting pituitary adenomas: Analysis of 429 surgically treated patients, effects of adjuvant treatment modalities and review of the literature
30. Defining postoperative values for successful resection of prolactinomas
31. Complications of transsphenoidal surgery: Results of a national survey, review of the literature, and personal experience
32. Indications for surgery in the treatment of hyperprolactinemia
33. Surgical treatment of pituitary prolactinomas: Postoperative prolactin and fertility in seventy patients
34. Bromocriptine treatment of prolactin-secreting tumors: Surgical implications
35. Resistance to bromocriptine in prolactinomas